Latest News
Conference Coverage
Long COVID risk not higher with rheumatic diseases
“The data demonstrate that rheumatic disease itself is not a risk factor for long COVID. However, patients with rheumatic diseases are at a higher...
Feature
When could you be sued for AI malpractice? You’re likely using it now
A record that clearly outlines how the physician incorporated the AI is critical if a claim later arises in which the doctor is accused of AI-...
Latest News
Blood biomarker may help predict who will develop Alzheimer’s
At this point, the biomarker is a research tool, but its application in clinical practice “is not very far away.”
Conference Coverage
Studies reveal nuances in efficacy, MACE risk between JAKi and TNFi
Three studies provide more data on risk for major adverse cardiovascular events with JAK inhibitors vs. TNF inhibitors, as well as their efficacy...
From the Journals
Gout linked to smaller brain volume, higher likelihood of neurodegenerative diseases
Patients with gout may have smaller brains with more iron, and they may be at increased risk for developing dementia and other neurodegenerative...
Latest News
Cell activity in psoriasis may predict disease severity and provide clues to comorbidities
Skin samples from patients with psoriasis showed more fibroblast clusters in the upper layers of the skin in moderate to severe cases.
Conference Coverage
Early axial spondyloarthritis diagnosis in referred patients remains stable in most
Patients who are diagnosed with axial spondyloarthritis after referral to a rheumatologist for chronic back pain most often keep that diagnosis,...
Conference Coverage
Investigational uricase-based gout drug meets primary endpoints in phase 3 trials
Two phase 3 trials of the once-monthly SEL-212 in refractory gout achieved and maintained serum uric acid < 6 mg/dL for ≥ 80% of the final...
Feature
MDs with chronic illness live in a different medical world
Along with the physically demanding schedule of medical practice, they must cope with what many call a “culture of invincibility” within medicine...
Conference Coverage
EULAR systemic sclerosis recommendations now include immunosuppressants
The update to 2017 recommendations include targeted synthetic and biologic DMARDs for the first time.
Conference Coverage
URAT1 inhibitor shows ‘substantial’ uric acid reduction in phase 2 gout trial
The investigational drug, AR882, reduced serum uric acid to levels seen in people without hyperuricemia and gout.